Mastocytosis is a group of disorders in which abnormal, clonally related mast cells accumulate in one or more tissues. It most commonly affects the skin and bone marrow, but may also involve the liver, spleen, gastrointestinal tract, and other organs. Clinical effects arise both from substances released by mast cells and, in advanced disease, from tissue infiltration that impairs organ function. The principal categories are cutaneous mastocytosis, confined to the skin, and systemic mastocytosis, involving at least one extracutaneous organ. The course ranges from childhood skin disease that may regress to uncommon, aggressive blood disorders.
Biological basis
Mast cells are tissue-resident cells of the immune system. They participate in allergic reactions, host defense, and inflammation. Their granules contain substances such as histamine and tryptase, and activated mast cells also produce additional inflammatory mediators.
In mastocytosis, abnormal mast cells arise from a common cellular precursor. Most adults with systemic disease have an acquired activating mutation in the KIT gene, especially the variant designated D816V. KIT is a receptor tyrosine kinase involved in mast-cell development and survival. Constitutive activation of this receptor promotes the persistence and accumulation of abnormal cells. Childhood cutaneous disease has a more varied mutation profile.
Mastocytosis is generally sporadic rather than inherited. Additional acquired mutations can occur in advanced systemic disease and may influence its behavior.
Two mechanisms account for much of the illness:
- Mediator release: mast-cell activation releases substances that can cause itching, flushing, abdominal symptoms, low blood pressure, and severe systemic reactions.
- Tissue infiltration: accumulation of abnormal mast cells can disrupt blood formation, liver function, intestinal absorption, or skeletal integrity.
The intensity of mediator-related symptoms does not necessarily correspond to the amount of mast-cell infiltration. Severe reactions can occur in people with otherwise low-burden disease.
Classification
Cutaneous mastocytosis
Cutaneous mastocytosis occurs predominantly in children, often beginning in infancy. Its main forms are:
- Maculopapular cutaneous mastocytosis: multiple pigmented spots or raised lesions; historically called urticaria pigmentosa.
- Diffuse cutaneous mastocytosis: widespread infiltration and thickening of the skin, sometimes accompanied by extensive blistering in infancy.
- Cutaneous mastocytoma: a localized accumulation of mast cells, usually appearing as a solitary raised lesion or a small number of lesions.
Childhood skin lesions frequently improve or disappear during adolescence, although persistence is possible. Adult-onset mastocytosis in the skin is more often associated with systemic involvement. Skin appearance alone therefore does not establish that disease is confined to the skin.
Systemic mastocytosis
Systemic mastocytosis is classified as a hematologic neoplasm. In this context, “neoplasm” denotes clonal cellular proliferation and does not mean that every case behaves as aggressive cancer.
Recognized forms include:
- Indolent systemic mastocytosis: systemic disease without organ damage attributable to mast-cell infiltration.
- Bone marrow mastocytosis: a low-burden form without typical skin lesions, recognized separately in the World Health Organization classification.
- Smoldering systemic mastocytosis: a greater disease burden than indolent disease, but without the organ damage that defines aggressive disease.
- Aggressive systemic mastocytosis: mast-cell infiltration causes clinically significant organ dysfunction.
- Systemic mastocytosis with an associated hematologic neoplasm: mastocytosis coexists with another blood neoplasm, commonly of myeloid origin, such as a myelodysplastic syndrome.
- Mast cell leukemia: a rare, highly aggressive form with a large proportion of mast cells in bone marrow aspirates, with or without substantial circulating mast cells.
Terminology and category boundaries differ somewhat between the World Health Organization and International Consensus Classification systems. Mast cell sarcoma is a separate, exceptionally rare destructive mast-cell tumor rather than a usual subtype of systemic mastocytosis.
Clinical manifestations
Skin and mediator-related symptoms
Typical skin lesions are tan, reddish-brown, or yellow-brown. Rubbing an involved area may cause localized swelling, redness, and itching, known as Darier’s sign. This sign supports the diagnosis in an appropriate setting but is not present in every case.
Mediator-related manifestations include:
- Itching, flushing, and episodes resembling urticaria.
- Cramping abdominal pain, nausea, and diarrhea.
- Palpitations, lightheadedness, and episodes of low blood pressure.
- Anaphylaxis, sometimes with little or no prominent skin reaction.
Heat, friction, alcohol, insect stings, and certain medications may provoke symptoms in some individuals, but triggers vary considerably. Mastocytosis is associated with an increased risk of severe reactions to Hymenoptera venom, including bee and wasp stings.
Skeletal and organ involvement
Osteoporosis and vertebral fractures can occur even in nonadvanced systemic disease. Bone abnormalities may also include areas of increased density or, less commonly, destructive lesions.
Advanced systemic disease can cause enlargement of the liver or spleen, impaired liver function, fluid accumulation in the abdomen, and malabsorption with weight loss. Bone marrow dysfunction may produce anemia, low platelet counts, or other blood-count abnormalities.
Organ enlargement alone is not equivalent to organ damage. Classification depends on whether abnormalities reflect disease burden or actual impairment attributable to mast-cell infiltration.
Diagnosis
Diagnosis integrates clinical findings, tissue examination, laboratory testing, and molecular analysis. No single symptom or routine blood test is sufficient in all cases.
Tissue and molecular findings
A skin biopsy can establish mast-cell accumulation in a suspicious skin lesion. Evaluation of systemic disease commonly includes bone marrow sampling, with histopathology, immunophenotyping, and testing for KIT mutations.
The major World Health Organization diagnostic criterion for systemic mastocytosis is the presence of multifocal dense aggregates containing at least 15 mast cells in bone marrow or another extracutaneous organ. Minor criteria concern:
- Abnormal mast-cell morphology.
- An activating KIT mutation.
- Aberrant expression of markers such as CD25, CD2, or CD30 on mast cells.
- Persistently elevated baseline serum tryptase above 20 ng/mL, subject to specified qualifications.
Under this framework, diagnosis generally requires the major criterion plus at least one minor criterion, or at least three minor criteria. International Consensus Classification rules differ in some details, including the role of the major criterion.
Tryptase and diagnostic limitations
Baseline serum tryptase is a useful biomarker, but it is not specific for mastocytosis. It may be elevated in hereditary alpha-tryptasemia and other conditions. Diagnostic interpretation accounts for known hereditary alpha-tryptasemia, and the tryptase criterion has restrictions when an associated myeloid neoplasm is present.
A transient tryptase increase during an acute reaction indicates mast-cell activation rather than, by itself, mastocytosis. Conversely, a normal baseline result does not exclude low-burden systemic disease.
Sensitive molecular assays can detect low levels of KIT D816V in peripheral blood. A negative blood result does not exclude disease when the abnormal cell population is small.
Distinction from mast cell activation syndrome
Mast cell activation syndrome concerns recurrent systemic episodes caused by mast-cell mediator release, supported by biochemical evidence and other diagnostic criteria. It is not synonymous with mastocytosis, which requires evidence of an abnormal mast-cell accumulation or clone meeting tissue-based criteria.
The conditions can coexist, but many people evaluated for mast-cell activation do not have mastocytosis.
Treatment
Treatment has two broad aims: controlling mediator-related manifestations and, when necessary, reducing the abnormal mast-cell population. Its selection depends on subtype, symptom burden, organ function, and molecular findings.
Antihistamines are widely used for mediator-related symptoms. Other approaches include drugs that reduce gastric acid, mast-cell stabilizing agents, and leukotriene-directed therapies. Epinephrine is the first-line treatment for anaphylaxis; it treats the acute reaction rather than the underlying mast-cell proliferation.
For systemic disease requiring reduction of the abnormal cell population, treatments include KIT-directed inhibitors such as midostaurin and avapritinib. Their indications differ by disease subtype and regulatory jurisdiction. Avapritinib also has an indication for adults with indolent systemic mastocytosis in some jurisdictions. Imatinib is relevant only to selected molecular settings because the common KIT D816V variant is resistant to it.
Other cytoreductive treatments include cladribine and, in selected circumstances, interferon alfa. Hematopoietic stem cell transplantation is used in selected patients with advanced disease. An associated hematologic neoplasm may require treatment directed at that neoplasm as well as at mastocytosis.
Prognosis and epidemiology
Mastocytosis is rare, and estimates of its frequency vary with diagnostic definitions, access to specialist testing, and recognition of mild disease.
Prognosis depends strongly on subtype. Childhood cutaneous mastocytosis often improves over time. Indolent systemic mastocytosis generally has a favorable outlook, although severe mediator symptoms and skeletal complications can substantially affect daily life. Progression to advanced disease occurs in a minority of patients.
Aggressive systemic mastocytosis, mast cell leukemia, and disease with an associated hematologic neoplasm have less favorable outcomes. Prognostic assessment incorporates organ damage, blood counts, age, molecular findings, and the nature of any accompanying blood disorder.